Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction

被引:30
|
作者
Shinozaki, Norihiko [1 ]
Ichinose, Hiroyuki [1 ]
Yahikozawa, Kumiko [1 ]
Shimada, Hirohide [1 ]
Hoshino, Kazuo [1 ]
机构
[1] Naganoken Koseiren Shinoni Gen Hosp, Dept Cardiol, Nagano 388, Japan
关键词
nitroprusside; slow reflow; no reflow; primary angioplasty; percutaneous coronary intervention; acute myocardial infarction;
D O I
10.1536/ihj.48.423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Previous studies have shown that intracoronary nitroprusside injection is safe and effective after slow reflow complicates percutancous coronary intervention (PCI). Objectives: We sought to determine the safety and efficacy of selective intracoronary administration of nitroprusside through the drug delivery catheter before balloon dilatation to prevent no or slow reflow during PCI for acute myocardial infarction (AMI). Methods: We studied 120 consecutive patients with AMI treated by PCI. In 60 patients (nitroprusside group), nitroprusside (120 mu g) was selectively administered through the drug delivery catheter into the distal coronary artery to reach the target lesion before balloon dilatation. Clinical and angiographic data, as well as in-hospital outcomes, of the nitroprusside group were retrospectively compared with 60 patients who had conventional PCI without nitroprusside (control group). Results: There were no significant differences in the baseline clinical and angiographic characteristics between the 2 groups. Compared to the control group, the nitroprusside group had 1) less slow reflow during the procedure (12% versus 35%, P = 0.0025), 2) a shorter fluoroscopic time (14.4 +/- 7.9 versus 18.7 +/- 9.1 minutes, P = 0.0093), 3) a shorter procedure time (57.6 +/- 20.6 versus 78.1 +/- 26.4, P < minutes, P < 0.0001), 4) a better final TIMI flow grade (III:II:I:0 = 59:1:0:0 versus 53:6:1:0, P = 0.0284), 5) a betterblush grade (III:II:I:0 = 49:10:1:0 versus 33:15:8:4, P = 0.0006), and 6) a better corrected TIMI coronary flame count (30.8 +/- 13.7 versus 46.5 +/- 44.7, P = 0.0102). There were no particular complications with nitroprusside use. Conclusions: The selective intracoronary administration of nitroprusside prior to PCI is safe and well tolerated, prevents no or slow reflows, and improves reperfusion of the infarcted myocardium.
引用
收藏
页码:423 / 433
页数:11
相关论文
共 50 条
  • [1] Selective Intracoronary Administration of Nitroprusside Before Balloon Dilatation Prevents Slow Reflow During Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
    Shinozaki, Norihiko
    Ichinose, Hiroyuki
    Hiramori, Seiichi
    Yahikozawa, Kumiko
    Hoshino, Kazuo
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (9A): : 32B - 32B
  • [2] Impact of Intracoronary Administration of Nitroprusside vs Nitroglycerine before Balloon Dilatation on Slow Reflow During Percutaneous Coronary Intervention in Patients with Acute ST Elevation Myocardial Infarction.
    Fischer, Louie
    Sudhakar, M.
    Sitaram, M.
    Shivkumar, J.
    Arunachalam, E.
    Prasad, Ravi
    Shaloob, Muhamed
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (8A): : 7A - 7A
  • [3] IMPACT OF INTRACORONARY ADMINISTRATION OF NITROPRUSSIDE VS. NITROGLYCERINE BEFORE BALLOON DILATATION ON SLOW REFLOW DURING PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE ST ELEVATION MYOCARDIAL INFARCTION
    Sai, Sudhakar
    Fischer, L.
    Shivkumar, J.
    Shivkumar, J.
    Vishnuarunachalam, R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E988 - E988
  • [4] Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction
    FU Xiang-hua FAN Wei-ze GU Xin-shun WEI Yong-yun JIANG Yun-fa WU Wei-li LI Shi-qiang HAO Guo-zhen WEI Qing-min XUE Ling Department of Cardiology
    中华医学杂志(英文版), 2007, (14) : 1226 - 1231
  • [5] Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction
    Fu Xiang-hua
    Fan Wei-ze
    Gu Xin-shun
    Wei Yong-yun
    Jiang Yun-fa
    Wu Wei-li
    Li Shi-qiang
    Hao Guo-zhen
    Wei Qini-min
    Ling, Xue
    CHINESE MEDICAL JOURNAL, 2007, 120 (14) : 1226 - 1231
  • [6] Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction
    FU Xianghua FAN Weize GU Xinshun WEI Yongyun JIANG Yunfa WU Weili LI Shiqiang HAO Guozhen WEI Qingmin XUE Ling Department of CardiologySecond Hospital of Hebei Medical UniversityInsistitute of Hebei Province of CardioCerebrovascular DiseaseShijiazhuang China Fu XH Fan WZ Gu XS Wei YY Jiang YF Wu WL Li SQ Hao GZ Wei QM Xue L
    Chinese Medical Journal, 2007, 120 (14) : 1226 - 1231
  • [7] Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction
    Wang, HJ
    Lo, PH
    Lin, JJ
    Lee, H
    Hung, JS
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 63 (02) : 171 - 176
  • [8] THE EFFECT OF SELECTIVE INTRACORONARY NITROPRUSSIDE INJECTION DURING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE MYOCARDIAL INFARCTION ON LEFT VENTRICULAR REMODELING
    Shinozaki, Norihiko
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E43 - E43
  • [9] The Use of Intracoronary Sodium Nitroprusside to Treat No-Reflow after Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
    Tesic, Milorad B.
    Stankovic, Goran
    Vukcevic, Vladan
    Ostojic, Miodrag C.
    HERZ, 2010, 35 (02) : 114 - 118
  • [10] Effects of Early Intracoronary Administration of Nicorandil During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
    Feng, Chunguang
    Liu, Yi
    Wang, Lulu
    Niu, Dongdong
    Han, Bing
    HEART LUNG AND CIRCULATION, 2019, 28 (06): : 858 - 865